Meeting
2012 Gastrointestinal Cancers Symposium
Outcome of trimodality-eligible esophagogastric cancer (EC) patients who declined surgery after preoperative chemoradiation.
Authors
Takashi Taketa
University of Texas M. D. Anderson Cancer Center, Houston, TX
Takashi Taketa , Arlene M Correa , Akihiro Suzuki , Mariela Anabel Blum , Jeffrey Edwin Lee , James Welsh , Steven H. Lin , Dipen Maru , Jeremy J. Erasmus , Manoop S. Bhutani , Brian Weston , David C. Rice , Stephen Swisher , Wayne Lewis Hofstetter , Jaffer A. Ajani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 6)
DOI
10.1200/jco.2012.30.4_suppl.6
Abstract #
6
Poster Bd #
A8
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
16-covariate propensity score matching between trimodality (TMT)-eligible esophagogastric cancer (EC) patients who had surgery and those who declined surgery after preoperative chemoradiation.
First Author: Takashi Taketa
Poster
2023 ASCO Annual Meeting
Expression molecular subtype as a predictor of outcomes of chemoradiotherapy for esophageal cancer.
First Author: Manabu Muto
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trimodality therapy with carboplatin/paclitaxel (CP) or FOLFOX (FFX) for esophageal/esogastric junctional cancer (EC/EGJ): Expanded safety and efficacy data from PROTECT.
First Author: Antoine Adenis
Poster
2022 ASCO Annual Meeting
Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.
First Author: Antoine Adenis